ANDA 206801, held by Fresenius Kabi USA. Palonosetron Hydrochloride.
As of Nov 16, 2026, ANDA 206801 (Palonosetron Hydrochloride), held by Fresenius Kabi USA, was first approved by FDA on Sep 19, 2018, with 1 approved supplement and 0 published complete response letters.
1. INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Palonosetron HydrochlorideEQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) · injectable;intravenous | Palonosetron Hydrochloride | Rx |
| Sep 21, 2026 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 19, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters